| Literature DB >> 35682133 |
Abstract
Heart failure (HF) patients should be systematically educated before discharge on how to manage with standard written materials for patient self-management. However, because of the absence of readily available written materials to reinforce their learned knowledge, patients with HF feel inadequately informed in terms of the discharge information provided to them. This study aimed to develop core content to prepare patients with HF for transition from hospital to home care. The content was validated by expert panelists using Delphi methods. Nineteen draft items based on literature review were developed. We established a consensus on four core sections, including 47 categories and 128 subcategories through the Delphi survey: (1) understanding HF (five categories and 23 subcategories), (2) HF medication (19 categories and 45 subcategories), (3) HF management (20 categories and 47 subcategories), and (4) HF diary (three categories and 13 subcategories). Each section provided easy-to-understand educational contents using cartoon images and large or bold letters for older patients with HF. The developed core HF educational contents showed high consensus between the experts, along with clinical validity. The contents can be used as an educational booklet for both planning discharge education of patients with HF and for post-discharge management when transitioning from hospital to home. Based on this study, a booklet series for HF patients was first registered at the National Library of Korea. Future research should focus on delivering the core content to patients with HF in convenient and accessible format through various media.Entities:
Keywords: heart failure; patient education; transitional care
Mesh:
Year: 2022 PMID: 35682133 PMCID: PMC9180106 DOI: 10.3390/ijerph19116550
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Final content of heart failure discharge education after the first round.
| Section | Categories and Subcategories | |
|---|---|---|
| I. Understanding HF | 1. Definition | |
| (1) Anatomy and physiology of the heart, (2) Mechanism of disease | ||
| 2. Cause and risk factor | ||
| (1) Coronary diseases, (2) Cardiomyopathy, (3) Valvular diseases | ||
| 3. Signs and symptoms | ||
| (1) Main symptoms: | ||
| 4. Screening and diagnosis | ||
| (1) History taking and physical examination, (2) Electrocardiography | ||
| 5. Treatment | ||
| (1) Medications, (2) Medical and surgical procedures: | ||
| II. Medication treatments of HF | 1. Importance of medication treatments | |
| 2. Medications for HF in major organs | ||
| (1) Heart and coronary artery, (2) Kidney, (3) Blood vessels | ||
| 3. Type of HF medications | ||
| (1) Medication for increasing survival rate: | ||
| 4. Angiotensin-converting enzyme inhibitor | ||
| (1) Mechanism of drug action, (2) Name (generic and trade) | ||
| 5. Angiotensin receptor blocker | ||
| (1) Mechanism of drug action, (2) Name (generic and trade) | ||
| 6. Beta Blocker | ||
| (1) Mechanism of drug action, (2) Name (generic and trade) | ||
| 7. Angiotensin receptor neprilysin inhibitor | ||
| (1) Mechanism of drug action, (2) Name (generic and trade) | ||
| 8. Mineralocorticoid antagonist | ||
| (1) Mechanism of drug action, (2) Name (generic and trade) | ||
| 9. Selective if channel blocker | ||
| (1) Mechanism of drug action, (2) Name (generic and trade) | ||
| 10. Diuretics | ||
| (1) Mechanism of drug action, (2) Name (generic and trade), (3) Adverse action and medication interactions related with potassium ion | ||
| 11. Cardiotonic | ||
| (1) Mechanism of drug action, (2) Name (generic and trade), (3) Adverse action and therapeutic digoxin level | ||
| 12. Anticoagulant | ||
| (1) Mechanism of drug action, (2) Name (generic and trade), (3) Adverse action, therapeutic level, and medication interactions related with Vitamin K | ||
| 13. Calcium channel blocker | ||
| (1) Mechanism of drug action, (2) Name (generic and trade) | ||
| 14. Combination tablets | ||
| (1) Mechanism of drug action, (2) Name (generic and trade) | ||
| 15. Vasodilator | ||
| (1) Mechanism of drug action, (2) Name (generic and trade), (3) Nitroglycerin and use | ||
| 16. How to take medications | ||
| (1) Every day right on time and right methods, (2) Do not stop taking medicines by yourself | ||
| 17. Identifying patients’ medications | ||
| (1) Medication related with HF, (2) Other medications | ||
| 18. Monitoring side effects of medication treatments | ||
| (1) Dizziness, (2) Hyperkalemia, (3) Dry cough related to angiotensin-converting enzyme, (4) Dehydration related with diuretics, (5) Bradycardia related with beta blocker | ||
| 19. Medication interactions | ||
| (1) Other medications: OTC drug, (2) Foods, health functional foods, and health supplements | ||
| III. Management of HF | 1. Monitoring signs and symptoms | |
| (1) Stable status, (2) Caution status, (3) Emergency status | ||
| 2. Monitoring blood pressure | ||
| (1) Importance of checking BP, (2) How to measure BP, (3) Precaution when measuring BP | ||
| 3. Monitoring body weight for body fluid | ||
| (1) Importance of checking BW, (2) Ideal dry BW | ||
| 4. Monitoring edema | ||
| (1) How to assess edema, (2) How to control edema | ||
| 5. Monitoring urine volume | ||
| (1) Checking urine volume | ||
| 6. Monitoring blood glucose | ||
| 7. Restricting fluid intake | ||
| (1) How much water fluid is restricted? | ||
| 8. Restricting sodium intake | ||
| (1) How much sodium is restricted? (2) Relation between salt and sodium, (3) Low-salt diet at home and on eating out, (4) Sodium ranking in food | ||
| 9. Restricting fat and cholesterol | ||
| (1) Relation between cardiovascular health and fat/cholesterol, (2) Type of cholesterol and normal range, (3) How to control fat and cholesterol in foods | ||
| 10. HF patient-tailored diet control | ||
| (1) Selecting foods by each food group, (2) Question and answer when difficulty in eating meal, (3) How to read nutrient labeling in processed foods: sodium | ||
| 11. Exercise for HF | ||
| (1) Importance of exercise, (2) Recommended exercise, (3) Cautions for exercising, (4) Stretching before exercise | ||
| 12. No smoking | ||
| (1) Health effects by duration of smoking cessation | ||
| 13. Reduc or stop drinking | ||
| (1) Alcohol effects on the heart, (2) Caloric ranking in alcohol beverage | ||
| 14. Importance of preventing flu and pneumonia | ||
| (1) Hand washing, (2) Wearing mask *, (3) Brushing teeth *, (4) Vaccination | ||
| 15. Work-life balance in HF | ||
| 16. Sex and intimacy after HF | ||
| 17. Checking activities of daily living (K-IADL) * | ||
| 18. Expression the emotions | ||
| (1) Importance of expressing the emotions, (2) Checking the emotions (PHQ-9) | ||
| 19. Stress management and overcome * | ||
| (1) Stress and heart burden *, (2) Physical changes under stress *, (3) How to reduce stress *, (4) Muscle relaxation *, (5) Suitable rest and comfortable clothes, (6) Resting | ||
| 20. What a primary caregiver should do | ||
| (1) Checking if patient takes medications, (2) Observing for patient change signs and symptoms, (3) Assisting in low-salt diet control, (4) Helping with physical activity and exercise, (5) Emotional support, (6) Checking and helping with OPD follow-up * | ||
| IV. HF diary | 1. Written oath | |
| 2. Review of monitoring HF symptoms | ||
| (1) Caution condition status, (2) Emergency condition status | ||
| 3. Daily check | ||
| (1) Body weight, (2) Blood pressure and pulse rate, (3) Taking medicines, (4) Restricting fluid intake, (5) Monitoring sodium intake, (6) Urine volume, (7) Exercise, (8) No smoking, (9) Reduce or stop drinking, (10) Mood status, (11) Monitoring signs and symptoms | ||
* Newly added items in round 1. BNP, b-type natriuretic peptide; BP, blood pressure; BW, body weight; CT, computed tomography; HF, heart failure; K-IADL, Korea instrumental activities of daily living; MRI, magnetic resonance imaging; NT-proBNP, n-terminal prohormone of brain natriureptic peptide; NYHA, New York heart association; OTC, over-the-counter; PHQ-9, patient health questionnaire-9.
Results of the second and third rounds of the Delphi survey (N = 10).
| Contents | Categories | Second Round | Third Round | ||||
|---|---|---|---|---|---|---|---|
| M ± SD | CVR | CV | M ± SD | CVR | CV | ||
| I. Understanding HF | 1. Definition | 4.50 ± 0.527 | 1 | 0.12 | 4.70 ± 0.483 | 1 | 0.10 |
| 2. Cause and risk factors | 4.50 ± 0.527 | 1 | 0.12 | 4.70 ± 0.483 | 1 | 0.10 | |
| 3. Signs and symptoms | 4.50 ± 0.527 | 1 | 0.12 | 4.80 ± 0.422 | 1 | 0.09 | |
| 4. Screening and diagnosis | 4.40 ± 0.516 | 1 | 0.12 | 4.70 ± 0.483 | 1 | 0.10 | |
| 5. Treatment | 4.40 ± 0.516 | 1 | 0.12 | 4.70 ± 0.483 | 1 | 0.10 | |
| II. Medication treatments of HF | 1. Importance of medication treatments | 4.90 ± 0.316 | 1 | 0.06 | 4.90 ± 0.316 | 1 | 0.06 |
| 2. Medications for HF in major organ | 4.70 ± 0.483 | 1 | 0.10 | 4.90 ± 0.316 | 1 | 0.06 | |
| 3. Type of HF medications | 4.70 ± 0.483 | 1 | 0.10 | 4.90 ± 0.316 | 1 | 0.06 | |
| 4. Angiotensin-converting enzyme inhibitor | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 5. Angiotensin receptor blocker | 4.80 ± 0.422 | 1 | 0.09 | 5.00 ± 0.00 | 1 | 0.00 | |
| 6. Beta blocker | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 7. Angiotensin receptor neprilysin inhibitor | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 8. Mineralocorticoid antagonist | 4.80 ± 0.422 | 1 | 0.09 | 5.00 ± 0.00 | 1 | 0.00 | |
| 9. Selective sinus node I(f) channel inhibitor | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 10. Diuretics | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 11. Cardiotonic | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 12. Anticoagulant | 4.60 ± 0.516 | 1 | 0.11 | 4.90 ± 0.316 | 1 | 0.06 | |
| 13. Calcium channel blocker | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 14. Combination tablets | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 15. Vasodilator | 4.80 ± 0.422 | 1 | 0.09 | 5.00 ± 0.00 | 1 | 0.00 | |
| 16. How to take medications | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 17. Identifying patients’ medications | 4.90 ± 0.316 | 1 | 0.06 | 4.90 ± 0.316 | 1 | 0.06 | |
| 18. Monitoring side effects of medication treatments | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 19. Medication interactions | 4.60 ± 0.516 | 1 | 0.11 | 4.80 ± 0.422 | 1 | 0.09 | |
| III. Management of HF | 1. Monitoring signs and symptoms | 4.90 ± 0.316 | 1 | 0.06 | 4.90 ± 0.316 | 1 | 0.06 |
| 2. Monitoring and checking blood pressure | 4.90 ± 0.316 | 1 | 0.06 | 4.90 ± 0.316 | 1 | 0.06 | |
| 3. Monitoring and checking body weight for body fluid | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 4. Monitoring and assessment of edema | 4.90 ± 0.316 | 1 | 0.06 | 4.90 ± 0.316 | 1 | 0.06 | |
| 5. Monitoring and checking urine volume | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 6. Monitoring and checking blood glucose | 4.70 ± 0.483 | 1 | 0.10 | 4.70 ± 0.483 | 1 | 0.10 | |
| 7. Restricting fluid intake | 4.90 ± 0.316 | 1 | 0.06 | 4.90 ± 0.316 | 1 | 0.06 | |
| 8. Restricting sodium intake: at home, at eating out | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 9. Restricting fat and cholesterol | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| 10. HF patient-tailored diet control | 4.70 ± 0.483 | 1 | 0.10 | 4.80 ± 0.422 | 1 | 0.09 | |
| 11. Exercise for HF | 4.70 ± 0.483 | 1 | 0.10 | 4.90 ± 0.316 | 1 | 0.06 | |
| 12. No smoking | 4.80 ± 0.422 | 1 | 0.09 | 5.00 ± 0.00 | 1 | 0.00 | |
| 13. Reduce or stop drinking | 4.80 ± 0.422 | 1 | 0.09 | 5.00 ± 0.00 | 1 | 0.00 | |
| 14. Importance of preventing flu and pneumonia | 4.90 ± 0.316 | 1 | 0.06 | 4.90 ± 0.316 | 1 | 0.06 | |
| 15. Working | 4.90 ± 0.316 | 1 | 0.06 | 4.90 ± 0.316 | 1 | 0.06 | |
| 16. Sex and intimacy | 4.70 ± 0.675 | 0.8 | 0.14 | 4.70 ± 0.675 | 0.8 | 0.14 | |
| 17. Checking activities of daily living | 4.90 ± 0.316 | 1 | 0.06 | 4.90 ± 0.316 | 1 | 0.06 | |
| 18. Expression emotions | 4.80 ± 0.422 | 1 | 0.09 | 4.80 ± 0.422 | 1 | 0.09 | |
| 19. Stress management | 4.80 ± 0.422 | 1 | 0.09 | 5.00 ± 0.00 | 1 | 0.00 | |
| 20. What a primary caregiver should do | 4.80 ± 0.422 | 1 | 0.09 | 4.90 ± 0.316 | 1 | 0.06 | |
| IV. HF diary | 1. Written oath | 4.70 ± 0.483 | 1 | 0.10 | 4.70 ± 0.483 | 1 | 0.10 |
| 2. Review of monitoring HF symptoms | 4.80 ± 0.422 | 1 | 0.09 | 5.00 ± 0.00 | 1 | 0.00 | |
| 3. Daily check for 100 days | 4.80 ± 0.422 | 1 | 0.09 | 5.00 ± 0.00 | 1 | 0.00 | |
CV, coefficient of variance; CVRs, content validity ratios; HF, heart failure; K-IADL, Korea instrumental activities of daily living.